A detailed history of Exane Derivatives transactions in Chemo Centryx, Inc. stock. As of the latest transaction made, Exane Derivatives holds 92 shares of CCXI stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92
Previous 92 -0.0%
Holding current value
$0
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 28, 2022

SELL
$18.38 - $40.5 $336,611 - $741,717
-18,314 Reduced 99.5%
92 $3,000
Q3 2021

Oct 26, 2021

SELL
$13.18 - $19.83 $7,090 - $10,668
-538 Reduced 2.84%
18,406 $314,000
Q2 2021

Jul 28, 2021

SELL
$9.59 - $50.88 $19,764 - $104,863
-2,061 Reduced 9.81%
18,944 $253,000
Q1 2021

Apr 30, 2021

BUY
$49.53 - $68.4 $49,084 - $67,784
991 Added 4.95%
21,005 $1.08 Million
Q4 2020

Jan 27, 2021

BUY
$47.25 - $65.16 $860,895 - $1.19 Million
18,220 Added 1015.61%
20,014 $1.24 Million
Q3 2020

Oct 06, 2020

BUY
$46.35 - $61.69 $8,435 - $11,227
182 Added 11.29%
1,794 $98,000
Q2 2020

Jul 10, 2020

SELL
$38.58 - $65.07 $19,945 - $33,641
-517 Reduced 24.28%
1,612 $92,000
Q1 2020

Apr 17, 2020

BUY
$32.73 - $50.78 $69,682 - $108,110
2,129 New
2,129 $85,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.